Soligenix announces encouraging preliminary results of heat stable Ebola vaccine

A biopharmaceutical company collaborating with Hawai'i scientists on an Ebola vaccine announced encouraging news about its vaccine today.

Tests on the vaccine, still in development, have shown it is able to retain its effectiveness without refrigeration. That is a real plus when you are talking about many rural areas in Africa that are most at-risk for another Ebola outbreak.

"What we've just recently shown with the work performed with Soligenix, Inc. at the University of Colorado is that we can dry stabilize the key antigen for the Ebola vaccine so that it basically can be stored at room temperature or elevated temperature--you can almost leave it out in the sun --and it can be stable for up to three months," said Axel Lehrer, PhD, Assistant Professor, Department of Tropical Medicine, Medical Microbiology and Pharmacology at the University of Hawai'i at Mānoa John A. Burns School of Medicine (JABSOM).

The announcement was made by Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), which is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company is collaborating with the University of Hawai'i at Mānoa and Hawai'i Biotech, Inc. (HBI) to develop a heat stable subunit Ebola vaccine.

Soligenix said thermostabilization (heat stabilization) formulation studies, conducted with Dr. Theodore Randolph at the University of Colorado, have also shown that the use of thermostable formulations may allow full immunization to potentially be achieved with fewer vaccinations.

"None of the other Ebola vaccines under development have the ability to withstand high temperatures, which is an ongoing concern in areas of the world where Filoviruses are endemic," said Dr. Lehrer. "The ability to stabilize our vaccine candidate to retain immunogenicity may not only have an impact on logistics, but has also the potential to reach more persons at need. A vaccine that needs to be given fewer times increases the likelihood that more people receive sufficient doses of the vaccine to protect them from disease."

"We are very encouraged by these preliminary results and look forward to our continuing collaboration with Soligenix and HBI to further develop our Ebola and multivalent filovirus vaccines," said Dr. Lehrer.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
NIH launches Phase 1 trial for innovative nasal COVID-19 vaccine